TABLE 2

Abrocitinib and metabolites in pooled plasma, urine, and feces samples following a single oral dose of 200 mg 14C-abrocitinib (period A, n = 6)

AnalytePlasma
(% of Total Radioactivity)
Urineb
(% of Dose)
Fecesb
(% of Dose)
Total Urine/Feces
(% of Dose)
Abrocitinib25.80.60.30.9
M413.815.40.315.7
M2a12.413.50.514.0
M111.316.21.717.9
M3a4.84.50.34.8
M74.65.61.57.1
M63.412.20.813.0
372-12.50.70.20.9
358-12.01.10.11.2
356-1a1.51.70.21.9
356-21.53.30.63.9
M81.41.3nd1.3
340-51.00.40.20.6
M50.40.3nd0.3
  • Identified analytes ordered in relationship to prevalence in plasma.

  • nd, not detected.

  • aM2 and M3 are stereoisomers.

  • bOnly percentages of identified metabolites are reported.